Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.79 |
| ▸ | POLB | P06746 | 4/20 | 0.79 |
| ▸ | NPC1 | O15118 | 3/20 | 0.79 |
| ▸ | RAB9A | P51151 | 2/20 | 0.79 |
| ▸ | STAT1 | P42224 | 1/20 | 0.79 |
| ▸ | PDE2A | O00408 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.62 |
| ▸ | PKLR | P30613 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.60 |
| ▸ | ESR1 | P03372 | 1/20 | 0.60 |
| ▸ | APEX1 | P27695 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29853434 | 1.00 | MAPT (1.00) | MAPTKDM4EALDH1A1POLBNPC1 | |
| SCHEMBL26780124 | 0.94 | MAPT (0.89) | MAPTKDM4EALDH1A1POLBNPC1 | |
| SCHEMBL29853647 | 0.94 | MAPT (0.89) | MAPTKDM4EALDH1A1POLBNPC1 | |
| SCHEMBL17637792 | 0.90 | MAPT (0.81) | MAPTKDM4EALDH1A1POLBNPC1 | |
| SCHEMBL29853686 | 0.89 | KDM4E (1.00) | MAPTKDM4EALDH1A1POLBNPC1 | |
| SCHEMBL18880260 | 0.89 | KDM4E (1.00) | MAPTKDM4EALDH1A1POLBNPC1 | |
| SCHEMBL31408188 | 0.87 | MAPT (0.76) | MAPTKDM4EALDH1A1POLBNPC1 | |
| SCHEMBL31412887 | 0.86 | MAPT (0.74) | MAPTKDM4EALDH1A1POLBNPC1 | |
| SCHEMBL20430169 | 0.85 | MAPT (0.73) | MAPTKDM4EALDH1A1POLBNPC1 | |
| SCHEMBL26780127 | 0.84 | MAPT (0.72) | MAPTKDM4EALDH1A1POLBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12473269-B2 | Urolithin derivatives and methods of use thereof | VANDRIA SA (CH) | 2025-11-18 | — | — | US | disclosed |
| US-12358884-B2 | Urolithin derivatives and methods of use thereof | VANDRIA SA (CH) | 2025-07-15 | — | — | US | disclosed |
| US-12351567-B2 | Urolithin derivatives and methods of use thereof | VANDRIA SA (CH) | 2025-07-08 | — | — | US | disclosed |
| US-20240424006-A1 | USE OF UROLITHIN DERIVATIVES IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | VANDRIA SA (CH) | 2024-12-26 | — | — | US | disclosed |
| US-12036205-B2 | Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders | AMAZENTIS SA (CH) | 2024-07-16 | — | — | US | disclosed |
| US-12036205-B2 | Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders | AMAZENTIS SA (CH) | 2024-07-16 | — | — | US | disclosed |
| US-20240158364-A1 | UROLITHIN DERIVATIVES AND METHODS OF USE THEREOF | AMAZENTIS SA (CH) | 2024-05-16 | — | — | US | disclosed |
| US-20240158365-A1 | UROLITHIN DERIVATIVES AND METHODS OF USE THEREOF | AMAZENTIS SA (CH) | 2024-05-16 | — | — | US | disclosed |
| US-20240158363-A1 | UROLITHIN DERIVATIVES AND METHODS OF USE THEREOF | AMAZENTIS SA (CH) | 2024-05-16 | — | — | US | disclosed |
| US-20240139149-A1 | THERAPEUTIC USES OF UROLITHIN DERIVATIVES | VANDRIA SA (CH) | 2024-05-02 | — | — | US | disclosed |
| US-20120264819-A1 | Therapeutic Uses of Urolithins | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-10-18 | — | — | US | disclosed |
| US-20120164243-A1 | Compositions and Methods for Improving Mitochondrial Function and Treating Neurodegenerative Diseases and Cognitive Disorders | AMAZENTIS SA (CH) | 2012-06-28 | — | — | US | disclosed |
| US-20120164243-A1 | Compositions and Methods for Improving Mitochondrial Function and Treating Neurodegenerative Diseases and Cognitive Disorders | AMAZENTIS SA (CH) | 2012-06-28 | — | — | US | disclosed |
| US-8183282-B2 | Therapeutic uses of urolithins | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-22 | — | — | US | disclosed |
| US-20120069289-A1 | LIQUID CRYSTAL DISPLAY | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20120069289-A1 | LIQUID CRYSTAL DISPLAY | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-03-22 | — | — | US | disclosed |
| WO-2010133278-A1 | LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2010-11-25 | — | — | WO | disclosed |
| US-20090326057-A1 | THERAPEUTIC USES OF UROLITHINS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2009-12-31 | — | — | US | disclosed |
| EP-2068864-A2 | THERAPEUTIC USES OF UROLITHINS | The Regents of the University of California (US) | 2009-06-17 | — | — | EP | disclosed |
| WO-2007127263-A2 | THERAPEUTIC USES OF UROLITHINS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240424006-A1 | USE OF UROLITHIN DERIVATIVES IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | UBQLN2, SOD1, UBQLN1 | MAPT 114/4885KDM4E 4157/4885ALDH1A1 1601/4885 |
| US-12358884-B2 | Urolithin derivatives and methods of use thereof | NLN, UQCRC2, TUFM | MAPT 217/4885KDM4E 4333/4885ALDH1A1 851/4885 |
| US-20120164243-A1 | Compositions and Methods for Improving Mitochondrial Function and Treating Neurodegenerative Diseases and Cognitive Disorders | NLN, TUFM, TFAM | MAPT 65/4885KDM4E 2874/4885ALDH1A1 2051/4885 |
| US-20240158364-A1 | UROLITHIN DERIVATIVES AND METHODS OF USE THEREOF | NLN, UQCRC2, TUFM | MAPT 217/4885KDM4E 4333/4885ALDH1A1 851/4885 |
| US-20240158363-A1 | UROLITHIN DERIVATIVES AND METHODS OF USE THEREOF | NLN, UQCRC2, TUFM | MAPT 217/4885KDM4E 4333/4885ALDH1A1 851/4885 |
| US-20090326057-A1 | THERAPEUTIC USES OF UROLITHINS | UROD, UTS2R, PLAU | MAPT 1484/4885KDM4E 4122/4885ALDH1A1 234/4885 |
| US-12351567-B2 | Urolithin derivatives and methods of use thereof | NLN, UQCRC2, TUFM | MAPT 217/4885KDM4E 4333/4885ALDH1A1 851/4885 |
| US-20120264819-A1 | Therapeutic Uses of Urolithins | UROD, UTS2R, PLAU | MAPT 1484/4885KDM4E 4122/4885ALDH1A1 234/4885 |
| US-20240158365-A1 | UROLITHIN DERIVATIVES AND METHODS OF USE THEREOF | NLN, UQCRC2, TUFM | MAPT 217/4885KDM4E 4333/4885ALDH1A1 851/4885 |
| US-12473269-B2 | Urolithin derivatives and methods of use thereof | NLN, UQCRC2, TUFM | MAPT 217/4885KDM4E 4333/4885ALDH1A1 851/4885 |
| US-12036205-B2 | Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders | NLN, TUFM, TFAM | MAPT 65/4885KDM4E 2874/4885ALDH1A1 2051/4885 |
| US-20240139149-A1 | THERAPEUTIC USES OF UROLITHIN DERIVATIVES | TNNT2, TNNI3, TNNC1 | MAPT 1139/4885KDM4E 3913/4885ALDH1A1 747/4885 |
| US-20120069289-A1 | LIQUID CRYSTAL DISPLAY | LPXN, VCL, ACP3 | MAPT 38/4885KDM4E 2926/4885ALDH1A1 3543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.